Difference between revisions of "Nintedanib (Vargatef)"
m |
m |
||
| Line 6: | Line 6: | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *11/21/2014: Initial marketing authorization as Vargatef. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BIBF 1120 | *'''Code name:''' BIBF 1120 | ||
| − | *'''Brand names:''' Ofev, Vargatef | + | *'''Brand names:''' Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 22: | Line 25: | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 2014]] |
Revision as of 02:04, 5 December 2021
Not FDA approved for an antineoplastic indication at this time.
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).
Diseases for which it is used
History of changes in EMA indication
- 11/21/2014: Initial marketing authorization as Vargatef.
Also known as
- Code name: BIBF 1120
- Brand names: Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef